A few informed people on this forum have hinted at what could happen if someone has a mind to play ball, using us as the stumps.
Overnight a company called Allergan, did just what some here have been alluding to.
They bought two companies one of which, Tobira has been given fast track status by the FDA, but is still doing trials and there are no guarantees of their success.
http://www.marketwatch.com/story/al...um-to-buy-a-clinical-stage-biotech-2016-09-20
Yes they are in a completely different field, but the parallel is unavoidable.
In fact RAP is in a better situation because we have an unobtrusive device, and it is already proven to work.
I guess the point I am trying to make is, anybody who sells at the moment hoping to get back in, or people who short stop they're holdings could seriously live to regret it.
Just my opinion, DYOR.
Regards
Phil.
